In patients with T-NHL, high RBMX expression was associated with a normal white blood cell count (WBC normal vs. upper limit of normal: mean 193 vs. 118; p = 0.023) and non-response to first-line chemotherapy (resistant vs. sensitive: mean 178 vs. 128; p = 0.029). This evidence concerns the gene RBMX and non-Hodgkin lymphoma.